Korro Bio Inc Quick Ratio (KRRO) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Korro Bio Inc   (NASDAQ: KRRO)

Korro Bio Inc 's Quick Ratio

KRRO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 11.06 above Korro Bio Inc average.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Quick Ratio than Korro Bio Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 367, from total ranking in the second quarter 2026 at 427.

Explain Quick Ratio?
How much Cash & cash equivalents KRRO´s has?
What are KRRO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KRRO/financial-strength
https://api.csimarket.com/api/v1/companies/KRRO/fundamentals
https://api.csimarket.com/api/v1/companies/KRRO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KRRO Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 1.95 %
Y / Y Cash & cash equivalent Change 78.44 %
Quick Ratio MRQ 11.06
KRRO's Total Ranking # 367
Seq. Current Liabilities Change 18.17 %
Seq. Cash & cash equivalent Change 1.36 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 85
Healthcare Sector # 126
Overall Market # 367


Quick Ratio Statistics
High Average Low
18.7 8.12 2.29
(Jun 30 2021)   (Sep 30 2019)




Financial Statements
Korro Bio Inc 's Current Liabilities $ 15 Millions Visit KRRO's Balance sheet
Korro Bio Inc 's Cash & cash equivalent $ 165 Millions Visit KRRO's Balance sheet
Source of KRRO's Sales Visit KRRO's Sales by Geography


Cumulative Korro Bio Inc 's Quick Ratio

KRRO's Quick Ratio for the trailling 12 Months

KRRO Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -9.01 %
Y / Y Cash & cash equivalent TTM Growth 20.25 %
Quick Ratio TTM 9.52
Total Ranking TTM # 3777
Seq. Current Liabilities TTM Growth 0.53 %
Seq. Cash & cash equivalent TTM Growth 16.32 %

Quick ratio ranking by company, industry and sector >> Back to KRRO Financial Strength Comparisons >> Go to Compare KRRO Quick Ratio to its Competitors

On the trailing twelve months basis KRRO Cash & cash equivalent soared by 78.44 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Korro Bio Inc 's Quick Ratio to 9.52, above KRRO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Korro Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2620 to 3777.

Explain Quick Ratio?
How much Cash & cash equivalents KRRO´s has?
What are KRRO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 879
Within the Market # 3777


trailing twelve months Quick Ratio Statistics
High Average Low
9.95 5.27 2.41
(Dec 31 2021)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Korro Bio Inc   11.06 $ 165.015  Millions$ 14.923  Millions

Date modified: 2026-11-08T19:30:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.